JP2023508332A5 - - Google Patents

Info

Publication number
JP2023508332A5
JP2023508332A5 JP2022538232A JP2022538232A JP2023508332A5 JP 2023508332 A5 JP2023508332 A5 JP 2023508332A5 JP 2022538232 A JP2022538232 A JP 2022538232A JP 2022538232 A JP2022538232 A JP 2022538232A JP 2023508332 A5 JP2023508332 A5 JP 2023508332A5
Authority
JP
Japan
Prior art keywords
unsubstituted
cancer
substituted
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538232A
Other languages
English (en)
Japanese (ja)
Other versions
JP7750526B2 (ja
JP2023508332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065410 external-priority patent/WO2021127045A1/en
Publication of JP2023508332A publication Critical patent/JP2023508332A/ja
Publication of JP2023508332A5 publication Critical patent/JP2023508332A5/ja
Application granted granted Critical
Publication of JP7750526B2 publication Critical patent/JP7750526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538232A 2019-12-20 2020-12-16 組み合わせ Active JP7750526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952032P 2019-12-20 2019-12-20
US62/952,032 2019-12-20
PCT/US2020/065410 WO2021127045A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (3)

Publication Number Publication Date
JP2023508332A JP2023508332A (ja) 2023-03-02
JP2023508332A5 true JP2023508332A5 (cg-RX-API-DMAC7.html) 2023-12-25
JP7750526B2 JP7750526B2 (ja) 2025-10-07

Family

ID=76478077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538232A Active JP7750526B2 (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230054854A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069242A4 (cg-RX-API-DMAC7.html)
JP (1) JP7750526B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119420A (cg-RX-API-DMAC7.html)
CN (2) CN121102230A (cg-RX-API-DMAC7.html)
AU (1) AU2020404996B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022012283A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165474A1 (cg-RX-API-DMAC7.html)
IL (1) IL294094A (cg-RX-API-DMAC7.html)
MX (1) MX2022007623A (cg-RX-API-DMAC7.html)
TW (1) TWI875898B (cg-RX-API-DMAC7.html)
WO (1) WO2021127045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2945940B1 (en) 2013-01-16 2020-07-15 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112018008882A8 (pt) * 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
TWI773730B (zh) 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
IL316472A (en) * 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
BR112020018286A2 (pt) * 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2

Similar Documents

Publication Publication Date Title
JP2023508328A5 (cg-RX-API-DMAC7.html)
JP2021516242A5 (cg-RX-API-DMAC7.html)
RU2020120928A (ru) Бензамидные соединения
JP2023526283A5 (cg-RX-API-DMAC7.html)
JP7348906B2 (ja) フェロトーシス誘導活性を有する化合物およびそれらの使用方法
ES2591028T3 (es) Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas
TW202327569A (zh) 包含tead抑制劑的藥物組合及其用於癌症治療之用途
CN115916765A (zh) 吡啶或嘧啶类衍生物及其制备方法和用途
JP2023507797A5 (cg-RX-API-DMAC7.html)
TWI755788B (zh) 類鐸受體促效劑
RU2007134396A (ru) Химические соединения
RU2589713C2 (ru) Средство, усиливающее действие противоопухолевых средств
RU2018137687A (ru) Фармацевтические комбинации для лечения злокачественной опухоли
JP2023508327A5 (cg-RX-API-DMAC7.html)
JP2021513996A5 (cg-RX-API-DMAC7.html)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
WO1995003308A1 (fr) Derive de morphinane et application medicale
CA3126102A1 (en) Substituted polycyclic carboxylic acids, analogues thereof, and methods using same
CN114008024A (zh) 具有铁死亡诱导活性的化合物以及使用其的方法
ES2919572T3 (es) Compuestos antiproliferación y usos de los mismos
JP2022513845A (ja) 置換アリールメチル尿素およびヘテロアリールメチル尿素、その類似体、ならびにそれらを使用する方法
EP3793550A2 (en) Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
JP2024516828A (ja) がん治療のためのpcna阻害剤及びegfr阻害剤
JP2021512046A5 (cg-RX-API-DMAC7.html)
US10745433B2 (en) Compounds for inhibiting cancer and virus